Diagnosis and management of behavioral issues in frontotemporal dementia

Current Neurology and Neuroscience Reports

Volumn 12, Issue 5, 2012, Pages 528-536

  Manoochehri, Masood ^a   Huey, Edward D ^a  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

BvFTD; Diagnosis; Differential diagnosis; Frontotemporal dementia; Frontotemporal lobar degeneration; FTLD; Treatment

Indexed keywords

ARIPIPRAZOLE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DAVUNETIDE; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; LITHIUM SALT; MEMANTINE; METHYLPHENIDATE; OLANZAPINE; OXYTOCIN; PAROXETINE; PIRACETAM; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOLCAPONE; TRAZODONE; VALPROIC ACID;

AGITATION; ALZHEIMER DISEASE; APATHY; ARTICLE; BEHAVIOR THERAPY; CAREGIVER; COMPULSION; DIAGNOSTIC PROCEDURE; DIET; DISEASE MODEL; DRUG EFFICACY; DRUG TOLERABILITY; EMPATHY; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; HEALTH EDUCATION; HUMAN; MENTAL DISEASE; NEUROPROTECTION; NONHUMAN; PROGRESSIVE SUPRANUCLEAR PALSY; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; SINGLE DRUG DOSE; TAUOPATHY;

ALZHEIMER DISEASE; COGNITION; DIAGNOSIS, DIFFERENTIAL; FRONTOTEMPORAL DEMENTIA; HUMANS; SOCIAL BEHAVIOR;

EID: 84870573312     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0302-7     Document Type: Article

References (77)

1. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-54.
2. Rascovsky K, Hodges JR, Kipps CM, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord. 2007;21:S14-8. (Pubitemid 350307439)
3. Mendez MF, Shapira JS, McMurtray A, et al. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol. 2007;64:830-5. (Pubitemid 46919837)
4. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456-77. This paper presents new criteria for diagnosing bvFTD. The paper demonstrates that the criteria are more sensitive and presents data on the relative prevalance on behavioral symptoms in pathologically confirmed cases.
5. Mourik JC, Rosso SM, Niermeijer MF, et al. Frontotemporal dementia: behavioral symptoms and caregiver distress. Dement Geriatr Cogn Disord. 2004;18:299-306. (Pubitemid 39370305)
6. Adenzato M, Cavallo M, Enrici I. Theory of mind ability in the behavioural variant of frontotemporal dementia: an analysis of the neural, cognitive, and social levels. Neuropsychologia. 2010;48:2-12.
7. Rankin KP, Gorno-Tempini ML, Allison SC, et al. Structural anatomy of empathy in neurodegenerative disease. Brain. 2006;129:2945-56. (Pubitemid 44684515)
8. Huey ED, Armstrong N, Momeni P, Grafman J. Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008;12:1367-76.
9. Ikeda M, Brown J, Holland AJ, et al. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;73:371-6.
10. Mendez MF, Foti DJ. Lethal hyperoral behaviour from the Kluver-Bucy syndrome. J Neurol Neurosurg Psychiatry. 1997;62:293-4. (Pubitemid 27117269)
11. Piguet O. Eating disturbance in behavioural-variant frontotemporal dementia. J Mol Neurosci. 2011;45:589-93.
12. Piguet O, Petersen A, Yin Ka Lam B, et al. Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol. 2011;69:312-9.
13. Carey CL, Woods SP, Damon J, et al. Discriminant validity and neuroanatomical correlates of rule monitoring in frontotemporal dementia and Alzheimer's disease. Neuropsychologia. 2008;46:1081-7.
14. Lillo P, Hodges Jr. Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. J Clin Neurosci. 2009;16:1131-5.
15. Levy ML, Miller BL, Cummings JL, et al. Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol. 1996;53:687-90. (Pubitemid 26242221)
16. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10-6. (Pubitemid 27232698)
17. Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia. J Neurol Sci . 2005;236:43-8. (Pubitemid 41218691)
18. Bozeat S, Gregory CA, Ralph MA, Hodges Jr. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000;69:178-86. (Pubitemid 30466021)
19. Liscic RM, Storandt M, Cairns NJ, Morris JC. Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. Arch Neurol. 2007;64:535-40. (Pubitemid 46588342)
20. Mathias JL, Morphett K. Neurobehavioral differences between Alzheimer's disease and frontotemporal dementia: a meta-analysis. J Clin Exp Neuropsychol. 2010;32:682-98. This paper reviews studies over a 14-year period that included AD and FTD neurobehavioral measures. The paper finds that FTD-specific scales are best at discriminating between AD and FTD.
21. Kertesz A, Nadkarni N, Davidson W, Thomas AW. The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc. 2000;6:460-8. (Pubitemid 30394399)
22. Marczinski CA, Davidson W, Kertesz A. A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia. Cogn Behav Neurol. 2004;17:185-90. (Pubitemid 40066234)
23. De Deyn PP, Engelborghs S, Saerens J, et al. The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. Int J Geriatr Psychiatry. 2005;20:70-9. (Pubitemid 40089567)
24. Grace, J.a.M., P.F., Frontal Systems Behavioral Scale: Professional Manual. 2001, Lutz, FL: Psychological Assessment Resources, Inc.
25. National Alzheimer's Coordinating Center. Available at www.alz.-washington.edu. Accessed May 2012.
26. Chow TW, Pio FJ, Rockwood K. An international needs assessment of caregivers for frontotemporal dementia. Can J Neurol Sci. 2011;38:753-7.
27. Woolley JD, Khan BK, Murthy NK, et al. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72:126-33.
28. Salmon E, Perani D, Collette F, et al. A comparison of unawareness in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2008;79:176-9. (Pubitemid 351236549)
29. Koenigs M, Huey ED, Calamia M, et al. Distinct regions of prefrontal cortex mediate resistance and vulnerability to depression. J Neurosci. 2008;28:12341-8.
30. McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58:1803-9. (Pubitemid 33044246)
31. Lopez OL, Gonzalez MP, Becker JT, Reynolds CF, et al. Symptoms of depression and psychosis in Alzheimer's disease and frontotemporal dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:154-61. (Pubitemid 26232417)
32. Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135:693-708.
33. Panegyres PK, Graves A, Frencham KA. The clinical differentiation of fronto-temporal dementia from psychiatric disease. Neuropsychiatr Dis Treat. 2007;3:637-45. (Pubitemid 350090294)
34. Rankin KP, Santos-Modesitt W, Kramer JH, et al. Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias. J Clin Psychiatry. 2008;69:60-73. (Pubitemid 351281998)
35. Bei H, Ross L, Neuhaus J, et al. Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2010;25:128-33. This paper uses a large data set to determine the prevalence of medications used to treat bvFTD.
36. de Vugt ME, Riedijk SR, Aalten P, et al. Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;22:35-41.
37. Lopez-Pousa S, Calvo-Perxas L, Lejarreta S, et al. Use of antidementia drugs in frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen, 2012.
38. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17-22. (Pubitemid 43739585)
39. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931-7. (Pubitemid 39626373)
40. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84-7. (Pubitemid 46106094)
41. Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178-85. (Pubitemid 351196131)
42. Kerchner GA, Tartaglia MC, Boxer A. Abhorring the vacuum: use of Alzheimer's disease medications in frontotemporal dementia. Expert Rev Neurother. 2011;11:709-17.
43. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev, 2005: CD003154.
44. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21:164-6. (Pubitemid 46878979)
45. Diehl-Schmid J, Forstl H, Perneczky R, et al. A 6-month, openlabel study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23:754-9.
46. Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211-7.
47. Vercelletto M, Boutoleau-Bretonniere C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23:749-59.
48. Chow TW, Graff-Guerrero A, Verhoeff NP, et al. Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat. 2011;7:415-24.
49. ClinicalTrials.gov: Memantine (10 mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. Available at http://clinicaltrials.gov/ct2/ show/NCT00545974. Accessed May 2012
50. Sjogren M, Minthon L, Passant U, et al. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging. 1998;19:379-84. (Pubitemid 29065486)
51. Rinne JO, Laine M, Kaasinen V, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002;58:1489-93. (Pubitemid 34552954)
52. Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172:400-8. (Pubitemid 38650975)
53. Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13-9. (Pubitemid 35477963)
54. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212-6. (Pubitemid 27242008)
55. Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry, 2011.
56. Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742-5. (Pubitemid 41051787)
57. Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004;17:117-21. (Pubitemid 38339734)
58. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355-9. (Pubitemid 38721158)
59. O'Brien JT, Burns A, B.A.P.D.C. Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:997-1019.
60. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359-69.
61. Curtis RC, Resch DS. Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000;20:384-5. (Pubitemid 30318372)
62. Fellgiebel A, Muller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8:123-6. (Pubitemid 46681093)
63. Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205-14. (Pubitemid 37010729)
64. Mendez MF, Lipton A. Emergent neuroleptic hypersensitivity as a herald of presenile dementia. J Neuropsychiatry Clin Neurosci. 2001;13:347-56. (Pubitemid 32743713)
65. Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009;24:168-78.
66. Ikeda M, Tanabe H, Horino T, et al. Care for patients with Pick's disease-by using their preserved procedural memory. Seishin Shinkeigaku Zasshi. 1995;97:179-92.
67. Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2007;21:S64-9. (Pubitemid 350307447)
68. Mioshi E, Foxe D, Leslie F, et al. The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease. Alzheimer Dis Assoc Disord, 2012.
69. Knopman DS, Kramer JH, Boeve BF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008;131:2957-68.
70. Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651-8. (Pubitemid 43276981)
71. Gennatas ED, Cholfin JA, Zhou J, et al. COMT Val158Met genotype influences neurodegeneration within dopamine-innervated brain structures. Neurology. 2012;78:1663-9.
72. ClinicalTrials.gov: Effects of Tolcapone on Frontotemporal Dementia. Available at www.clinicaltrials.gov/ct2/show/NCT00604591. Accessed May 2012.
73. Finger EC. New potential therapeutic approaches in frontotemporal dementia: oxytocin, vasopressin, and social cognition. J Mol Neurosci. 2011;45:696-701.
74. Jesso S, Morlog D, Ross S, et al. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain. 2011;134:2493-501.
75. ClinicalTrials.gov: Safety Study of Intranasal Oxytocin in Frontotemporal Dementia. Available at http://clinicaltrials.gov/ct2/show/NCT01386333. Accessed May 2012.
76. Coccaro EF, Kavoussi RJ, Hauger RL, et al. Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects. Arch Gen Psychiatry. 1998;55:708-14. (Pubitemid 28364387)
77. Prichard ZM, Mackinnon AJ, Jorm AF, Easteal S. AVPR1A and OXTR polymorphisms are associated with sexual and reproductive behavioral phenotypes in humans. Mutation in brief no. 981. Online. Hum Mutat. 2007;28:1150.